000153635 001__ 153635
000153635 005__ 20240229123046.0
000153635 0247_ $$2doi$$a10.1038/s41375-020-0724-1
000153635 0247_ $$2pmid$$apmid:32034285
000153635 0247_ $$2ISSN$$a0887-6924
000153635 0247_ $$2ISSN$$a1476-5551
000153635 0247_ $$2altmetric$$aaltmetric:75428499
000153635 037__ $$aDKFZ-2020-00358
000153635 041__ $$aeng
000153635 082__ $$a610
000153635 1001_ $$aGoldschmidt, Hartmut$$b0
000153635 245__ $$aResponse-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial.
000153635 260__ $$aLondon$$bSpringer Nature$$c2020
000153635 3367_ $$2DRIVER$$aarticle
000153635 3367_ $$2DataCite$$aOutput Types/Journal article
000153635 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1597743295_11684
000153635 3367_ $$2BibTeX$$aARTICLE
000153635 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000153635 3367_ $$00$$2EndNote$$aJournal Article
000153635 500__ $$a2020 Jul;34(7):1853-1865
000153635 520__ $$aThe MM5 trial aimed at demonstrating a progression-free survival (PFS) difference in continued vs. response-adapted (in case of complete response, CR) lenalidomide (LEN) maintenance therapy (MT) in newly diagnosed, transplant-eligible multiple myeloma (MM). Patients were equally randomized to receive induction therapy with PAd (bortezomib/doxorubicin/dexamethasone) or VCD (bortezomib/cyclophosphamide/dexamethasone), high-dose melphalan and autologous blood stem cell transplantation, and LEN consolidation, followed by either LEN MT for a fixed duration of 2 years (LEN-2Y) or until achievement of CR (LEN-CR, intention-to-treat population n = 502): arms A1:PAd + LEN-2Y (n = 125), B1:PAd + LEN-CR (n = 126), A2:VCD + LEN-2Y (n = 126), B2:VCD + LEN-CR (n = 125). In the LEN-CR group (B1 + B2), n = 88/17.5% patients did not start or discontinued LEN MT due to CR. There was no PFS (p = 0.60, primary endpoint) nor overall survival (OS) (p = 0.15) difference between the four study arms. On pooled LEN MT strategies, OS (hazard ratio, hazard ratio [HR] = 1.42, p = 0.03) but not PFS (HR = 1.15, p = 0.20) was shorter in LEN-CR (B1 + B2) vs. LEN-2Y (A1 + A2) groups. PFS was shortened on landmark analyses from the start of LEN MT in patients being in CR in the LEN-CR group (LEN-CR vs. LEN-2Y, HR = 1.84, p = 0.02). OS from first progression was shortened in the LEN-CR vs. LEN-2Y group (HR = 1.60, p = 0.01). LEN MT should be applied beyond CR for at least 2 years.
000153635 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000153635 588__ $$aDataset connected to CrossRef, PubMed,
000153635 7001_ $$00000-0002-6226-1252$$aMai, Elias K$$b1
000153635 7001_ $$aDürig, Jan$$b2
000153635 7001_ $$aScheid, Christof$$b3
000153635 7001_ $$aWeisel, Katja C$$b4
000153635 7001_ $$0P:(DE-He78)a9f6104e5c2c26345dcb242e6bdcb2b2$$aKunz, Christina$$b5$$udkfz
000153635 7001_ $$aBertsch, Uta$$b6
000153635 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b7$$udkfz
000153635 7001_ $$aMerz, Maximilian$$b8
000153635 7001_ $$aMunder, Markus$$b9
000153635 7001_ $$aLindemann, Hans-Walter$$b10
000153635 7001_ $$aHügle-Dörr, Barbara$$b11
000153635 7001_ $$0P:(DE-He78)2ef631585610340ff425c9c31fcabd03$$aTichy, Diana$$b12$$udkfz
000153635 7001_ $$aGiesen, Nicola$$b13
000153635 7001_ $$aHose, Dirk$$b14
000153635 7001_ $$aSeckinger, Anja$$b15
000153635 7001_ $$aHuhn, Stefanie$$b16
000153635 7001_ $$aLuntz, Steffen$$b17
000153635 7001_ $$aJauch, Anna$$b18
000153635 7001_ $$aElmaagacli, Ahmet$$b19
000153635 7001_ $$aRabold, Bernhard$$b20
000153635 7001_ $$aFuhrmann, Stephan$$b21
000153635 7001_ $$aBrossart, Peter$$b22
000153635 7001_ $$aGoerner, Martin$$b23
000153635 7001_ $$aBernhard, Helga$$b24
000153635 7001_ $$aHoffmann, Martin$$b25
000153635 7001_ $$aHillengass, Jens$$b26
000153635 7001_ $$aRaab, Marc S$$b27
000153635 7001_ $$aBlau, Igor W$$b28
000153635 7001_ $$aHänel, Mathias$$b29
000153635 7001_ $$aSalwender, Hans J$$b30
000153635 7001_ $$aGroup, German-speaking Myeloma Multicenter$$b31$$eCollaboration Author
000153635 773__ $$0PERI:(DE-600)2008023-2$$a10.1038/s41375-020-0724-1$$n7$$p1853-1865$$tLeukemia$$v34$$x1476-5551$$y2020
000153635 909CO $$ooai:inrepo02.dkfz.de:153635$$pVDB
000153635 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a9f6104e5c2c26345dcb242e6bdcb2b2$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000153635 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000153635 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2ef631585610340ff425c9c31fcabd03$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000153635 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000153635 9141_ $$y2020
000153635 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000153635 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000153635 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLEUKEMIA : 2017
000153635 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000153635 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000153635 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000153635 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000153635 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000153635 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000153635 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000153635 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000153635 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000153635 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bLEUKEMIA : 2017
000153635 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x0
000153635 980__ $$ajournal
000153635 980__ $$aVDB
000153635 980__ $$aI:(DE-He78)C060-20160331
000153635 980__ $$aUNRESTRICTED